A boutique venture capital firm founded in 2015 in Hong Kong is currently investing from its $100M fund in early stage cross-border technology companies in TMT and MedTech. The firm generally participates in Series A rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing, and is actively seeking new opportunities from across the world with a focus on companies in China, U.S. and Europe. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand aboard. The firm expects to make 8 new investments in the next 6 months.

The firm is most interested in medical devices such as minimally invasive surgical instruments, artificial intelligence and robots, diagnostic tools; and mobile health innovations. The firm is seeking innovations that have completed prototype. The firm would also consider therapeutics for large disease markets with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm can work with incomplete teams and contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request right of priority distribution rights or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity and advisory firm, based in Zürich, Switzerland, which has been founded in 1999. Along with providing private equity, the firm serves also as a corporate development and financial advisor to life science and technology companies through the firm’s VC and PE network. The firm has a primary focus on the Life Science sector and actively supports early stage companies in development. The firm has managed a €40M fund and is fundraising to close a larger fund in 2016. The firm focuses on companies based in Europe, though it would be open to US-based companies that have interest in establishing themselves in the European market and may have strong ties to Europe (i.e. representatives or office in Europe, European vendors, etc.).

The firm has a general interest in Life Sciences, especially concentrating on biotech therapeutics, diagnostics and medical devices of all subsectors as well as digital healthcare opportunities. With regard to indications the firm is agnostic and has worked in the past in oncology, cardiovascular, anti-infective, autoimmune, CNS and in the field of vaccine technology. When investing, the firm prefers preclinical to early clinical stage companies that have a first proof-of-concept in-vitro or/and in-vivo. The company is focusing on seed round opportunities and spin-offs in which the firm could actively engage. It would be advantageous if the product and service offering is based on a proprietary platform technology. The firm will look at commercialized/late stage products or technology far down the development timeline especially with respect to its business development activities offering.

The firm prefers a management team with experience in the industry, though understands that at the seed stage, there will be gaps in the management team that the firm will help to fill with own resources or drawing on its extensive network in the industry. The firm will also look at assets spun out of institutions including universities and research institutions or the pharmaceutical industry, and will support the scientist entrepreneurs in business development by integrating with the company and delivering managerial support where necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate VC firm based in Asia is focused on aggregating technologies in women’s health. The firm invests from an evergreen fund and is a multi-stage investor. Typical investments range from USD 1-5 million, but the fund may make larger tranched investments in the case of therapeutic opportunities. The firm invests in companies worldwide and can act as either a lead investor or co-investor.

The firm is currently focused on building a cluster of technologies in women’s health, across the therapeutic, medical device, diagnostic and healthcare IT sectors. The firm is particularly interested in reproductive health, triple-negative breast cancer, and ovarian cancer, but will consider any opportunity in women’s health. The firm will invest in technologies at any stage of development, including very early-stage technologies. In the medtech space, the firm has a preference for 510k pathways but will look at PMA opportunities if the technology is sufficiently interesting.

The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with global distribution and scale up.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage seed fund based in Palo Alto, CA focuses on seed stage and sometimes Series A investments. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Mountain West has approximately $300 million in total assets available for investment. The firm typically makes equity investments in 3 to 4 companies every year, and it has flexibility in terms of capital structures. The average first investment in a company is $2 million- $3 million, though it can invest more or less, depending on the opportunity. The firm prefers to invest in seed and series A (early-stage) companies as an initial investment in a company, though it sometimes makes a first investment in a series B or C round. The firm primarily invests in US-based companies, but it will also consider global companies with a US presence.

The firm is currently looking for investment opportunities in medical devices, biopharma and diagnostics. The firm generally makes investments in product-focused companies in pre-clinical stages with prototypes or other available proof-of-concept work completed. It generally likes to invest in companies that can reach the market with the capital raised from this round of financing. The firm prefers device companies with a 510(k) pathway for regulatory approval, and it will opportunistically consider companies with PMA devices.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chicago-based VC firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests in the USA and Canada.

The firm is presently focused on technologies that involve an IT/software component, across the medical devices, diagnostics, and healthcare services sectors in addition to pure digital health opportunities. The firm is open to opportunities in any clinical indication. The firm is only interested in devices and diagnostics that have in-human data.

In the life science sector, the firm is not interested in early-stage opportunities; however the firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that founded in 2000 and is based in the US Midwest has assets under management of over $250 million, and closed a new fund in 2015. The fund typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $12 million throughout a portfolio company’s path to liquidity.

The fund is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has previously invested in drugs to treat cancer and cardiac disorders, and in minimally invasive medical devices. The fund does not invest in diagnostics, though may be interested in technology with real-time feedback for procedures.

The fund focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the fund is able to help entrepreneurs achieve near-term objectives that position their companies for exit.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com